Annual Changes to the NASDAQ Biotechnology Index
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Annual Changes to the NASDAQ Biotechnology Index
December 17, 2014 8:00 AM EST
Inovio Pharma (NASDAQ: INO) announced the appointment of Zane Yang, M.D. as Vice President, Clinical Development, Oncology. In this position, he will be responsible for advancing Inovio's oncology portfolio of DNA immunotherapies through clinical trials to commercialization. He will report to Dr. Mark Bagarazzi, Inovio's Chief Medical Officer.
Inovio is planning a phase III trial for its immunotherapy for a pre-cancer, known as cervical... More
December 15, 2014 8:59 AM EST
Alimera Sciences (Nasdaq: ALIM) announced that it has closed its offering of Series B Preferred Stock with Deerfield Management and certain of its affiliates (Deerfield). Alimera issued Deerfield an aggregate of 8,291.873 shares of Series B Preferred Stock for a purchase price of $6,030.00 per share, or an aggregate purchase price of approximately $50.0 million. Each share of Series B Preferred Stock is convertible into 1,000 shares of Alimera's common stock at any time at the option of the holder, provided that the... More
